HCV treatment in 2020: How to translate highly effective therapies into elimination strategies.

Abstract

The hepatitis C virus (HCV) is among the most common blood-borne infections worldwide and a major cause of cirrhosis and hepatocellular carcinoma. HCV was first identified in 1989. The current use of direct-acting antiviral agents (DAAs) to cure HCV reflects rapid diagnostic and therapeutic advances in a short period of time that is seen in few diseases. Both the cost and access to DAAs have improved since the introduction of these therapies in 2014. While HCV is very easy to treat, it will be difficult to eliminate worldwide. The tools exist to create strategies to treat and eliminate HCV as a public health threat; however, elimination of HCV will involve improving access to diagnostic testing for HCV with confirmation of active infection. Models of care will need to be revised from centralized, specialized care to decentralized, point-of-care treatment for HCV patients. These models should include clinics that care for populations with a high prevalence of HCV, such as those treating intravenous drug users, needle exchange services, community health centers, and prisons, in addition to primary care clinics. These care pathways are feasible because of the simplicity of pan-genotypic therapies for HCV that require minimal monitoring. Many countries and regions of the world have embarked on programs with the goal of achieving the World Health Organization target of elimination by 2030. Best practices in HCV elimination should be shared globally.